Recent progress in tumour vaccine development

I. Caroline Le Poole; Hemamalini Bommiasamy; W. Martin Kast

doi:10.1517/eoid.12.6.971.21786

Recent progress in tumour vaccine development

I. Caroline Le Poole^*, Hemamalini Bommiasamy, W. Martin Kast

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Immunotherapy offers an exciting opportunity to treat human cancer. Analysis of tumour-associated antigens is progressing. Assisted by animal models, such knowledge can be used to design tumour vaccines. By including adjuvants to increase immunogenicity, several tumours previously thought to be non-immunogenic are now considered targets for tumour vaccines. Newly acquired knowledge regarding dendritic cell physiology is incorporated in newly designed vaccines that are currently in Phase I and II trials. Such assessment provides the overall conclusion that tumour vaccines are safe and deserve a more prominent place in the sequel of treatments for human cancer.

Original language	English (US)
Pages (from-to)	971-981
Number of pages	11
Journal	Expert Opinion on Investigational Drugs
Volume	12
Issue number	6
DOIs	https://doi.org/10.1517/eoid.12.6.971.21786
State	Published - Jun 1 2003

Keywords

Adjuvants
Antibodies
Antigens
Dendritic cells
Immune monitoring
Immunotherapy
T cells
Tumour vaccine

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1517/eoid.12.6.971.21786

Cite this

@article{2c87298039fd447fbe25b2669cb39be1,

title = "Recent progress in tumour vaccine development",

abstract = "Immunotherapy offers an exciting opportunity to treat human cancer. Analysis of tumour-associated antigens is progressing. Assisted by animal models, such knowledge can be used to design tumour vaccines. By including adjuvants to increase immunogenicity, several tumours previously thought to be non-immunogenic are now considered targets for tumour vaccines. Newly acquired knowledge regarding dendritic cell physiology is incorporated in newly designed vaccines that are currently in Phase I and II trials. Such assessment provides the overall conclusion that tumour vaccines are safe and deserve a more prominent place in the sequel of treatments for human cancer.",

keywords = "Adjuvants, Antibodies, Antigens, Dendritic cells, Immune monitoring, Immunotherapy, T cells, Tumour vaccine",

author = "{Le Poole}, {I. Caroline} and Hemamalini Bommiasamy and Kast, {W. Martin}",

note = "Funding Information: Support by the Department of Defense (grant # DAMD 17-02-1-0244), the Illinois Department of Public Health, the National Vitiligo Foundation and the NCI grant (NCI PO1 CA 97296) is gratefully acknowledged.",

year = "2003",

month = jun,

day = "1",

doi = "10.1517/eoid.12.6.971.21786",

language = "English (US)",

volume = "12",

pages = "971--981",

journal = "Expert Opinion on Investigational Drugs",

issn = "1354-3784",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - Recent progress in tumour vaccine development

AU - Le Poole, I. Caroline

AU - Bommiasamy, Hemamalini

AU - Kast, W. Martin

N1 - Funding Information: Support by the Department of Defense (grant # DAMD 17-02-1-0244), the Illinois Department of Public Health, the National Vitiligo Foundation and the NCI grant (NCI PO1 CA 97296) is gratefully acknowledged.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Immunotherapy offers an exciting opportunity to treat human cancer. Analysis of tumour-associated antigens is progressing. Assisted by animal models, such knowledge can be used to design tumour vaccines. By including adjuvants to increase immunogenicity, several tumours previously thought to be non-immunogenic are now considered targets for tumour vaccines. Newly acquired knowledge regarding dendritic cell physiology is incorporated in newly designed vaccines that are currently in Phase I and II trials. Such assessment provides the overall conclusion that tumour vaccines are safe and deserve a more prominent place in the sequel of treatments for human cancer.

AB - Immunotherapy offers an exciting opportunity to treat human cancer. Analysis of tumour-associated antigens is progressing. Assisted by animal models, such knowledge can be used to design tumour vaccines. By including adjuvants to increase immunogenicity, several tumours previously thought to be non-immunogenic are now considered targets for tumour vaccines. Newly acquired knowledge regarding dendritic cell physiology is incorporated in newly designed vaccines that are currently in Phase I and II trials. Such assessment provides the overall conclusion that tumour vaccines are safe and deserve a more prominent place in the sequel of treatments for human cancer.

KW - Adjuvants

KW - Antibodies

KW - Antigens

KW - Dendritic cells

KW - Immune monitoring

KW - Immunotherapy

KW - T cells

KW - Tumour vaccine

UR - http://www.scopus.com/inward/record.url?scp=0038685907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038685907&partnerID=8YFLogxK

U2 - 10.1517/eoid.12.6.971.21786

DO - 10.1517/eoid.12.6.971.21786

M3 - Review article

C2 - 12783601

AN - SCOPUS:0038685907

SN - 1354-3784

VL - 12

SP - 971

EP - 981

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

IS - 6

ER -

Recent progress in tumour vaccine development

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this